Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
about
What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regressionRenal and neurological side effects of colistin in critically ill patientsParenteral colistin for the treatment of severe infections: a single center experience.Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyColistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.Baicalin inhibits colistin sulfate-induced apoptosis of PC12 cells.Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingThe use of intravenous colistin among children in the United States: results from a multicenter, case seriesColistin neurotoxicity: revisited.High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in Pediatric PatientsImpact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosaNephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patientsMulticentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolColistin use in pediatric intensive care unit for severe nosocomial infections: experience of an university hospital.Comparison of clinical characteristics of patients with acute kidney injury after intravenous versus inhaled colistin therapyMultidrug-resistant Gram-negative infections: the use of colistin.Emergent renal dysfunction with colistin pharmacotherapy.A review on colistin nephrotoxicity.Colistin: efficacy and safety in different populations.The safety of polymyxin antibiotics.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Ten years with colistin: a retrospective case series.Colistin nephrotoxicity in the ICU: Is it different in the geriatric patients?Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis.Variables determining the development of colistin-associated renal impairment.Nephrotoxicity of High and Conventional Dosing Regimens of Colistin: A Randomized Clinical Trial.Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration.Colistin nephrotoxicity increases with age.Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration.Nephrotoxicity associated with intravenous colistin in critically ill patients.The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative Infections
P2860
Q26999921-523586A2-BEBB-4D71-A66A-D72311FF4B9BQ27499294-9E01488C-FE16-41A0-BB6C-54567A632434Q33653353-7FE3030A-BB3C-410B-970C-150952AAC325Q33751736-27D70D69-3D98-4592-B027-4DA4A46F6BE6Q34015375-E5192C76-17D8-4305-B4AC-91DE22A6FBF0Q34095133-3AB474EF-59E3-443F-A977-68FB671F4EFDQ34552966-B7B56908-DF10-4E46-8CE8-AB726801C0E8Q35101242-5B47178C-0865-4723-A4B3-4D449D06C6EFQ35541277-5DCCBEF9-1DEB-4AC3-876F-BF2549E40725Q35592264-DCCB1D8C-07A9-4EA6-8525-B9C328F8AEFCQ35885209-0B4C56C2-D2EE-4512-A37E-1942438F5419Q35977417-C57B573E-B531-4F30-A971-2011510FD74DQ36229076-DE017CC8-2B69-4C7D-A672-5213297FDEA6Q36240813-F29AC57F-51A4-4668-A29E-4BAC974C9898Q36667079-0D27E900-59CC-4F19-B83A-4ADE3E3BCE27Q36818945-B6B0B2A0-2530-48B4-80EA-D0E8395BBCADQ37307919-28CEEF2C-2966-4418-8BD3-812B036A9EDBQ37480886-46DBD82E-FBDD-412E-96F6-778A91C8F739Q37785545-38A47094-500F-42D0-9240-2EE9B2B66A0BQ38100749-3E8E9C89-E150-4F9D-8A42-28F82B6A7E3EQ38501685-68C70C33-040F-4B6B-A78C-8450DA5C6EF4Q38514980-76001E36-DAF5-4A79-BF23-9D22A0D71A9EQ38586123-126E08FC-A97D-4992-A2FF-AC614D606509Q38672016-7D6476C3-B3BE-419A-A38B-BDCAE513790AQ39690212-7E5A3A75-DBA2-41CE-B5FA-415007228A04Q40069157-1D3497D1-52B2-4629-9875-C4F5992BDA9DQ40986687-E566AD3E-A356-4FE1-B9EA-D2536BAFA2D9Q41281850-81313DB8-6FCF-4CF1-A3CB-A77A080C01A9Q41990979-996C2D67-EE80-4800-AFCA-F3E16D1D9CB4Q42056256-4A05AC1F-FEA9-447D-A3FA-1019B51C67FBQ42204009-9F6235FF-4048-4536-BD8D-0F5AC4291307Q42256268-D878750D-FECE-438D-80DA-DB57C250CB1CQ42263849-929B791F-455B-40D6-90AE-E07C4D6B7C7DQ42762545-2B2198ED-18A4-445D-8ACB-12DBFC372E5FQ50990199-D3087F29-81BF-475D-8C1C-50826718A74BQ58801117-E8E70535-9167-41EB-902E-B417BBAF5DBB
P2860
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety and efficacy of intrave ...... negative bacterial infections.
@en
Safety and efficacy of intravenous colistin
@nl
type
label
Safety and efficacy of intrave ...... negative bacterial infections.
@en
Safety and efficacy of intravenous colistin
@nl
prefLabel
Safety and efficacy of intrave ...... negative bacterial infections.
@en
Safety and efficacy of intravenous colistin
@nl
P50
P1476
Safety and efficacy of intrave ...... negative bacterial infections.
@en
P2093
Chien-Yu Cheng
P304
P356
10.1016/J.IJANTIMICAG.2009.11.016
P577
2009-12-31T00:00:00Z